Japan · Delayed Price · Currency is JPY Adeka Earnings Call Transcripts
Fiscal Year 2027
-
Sales and profit grew in Q1 FY2026, driven by chemicals and life science. Full-year forecasts and dividends were raised, with strong segment performance and ongoing investments in growth. Risks include raw material costs and market uncertainties.
Fiscal Year 2026
-
FY2025 delivered record sales and profits, with Life Science and Environmental Materials offsetting weakness in Polymer Additives and Semiconductor Materials. FY2026 forecasts further growth, but exclude Middle East impacts; annual dividends are forecast at JPY 120/share.
-
Net sales rose slightly year-over-year, but operating profit declined due to higher fixed costs. Guidance for full-year sales and profit was revised downward, with recovery expected in Q4, especially in polymer additives and semiconductor materials.
-
First-half FY2025 saw modest sales and profit growth, led by strong life science results offsetting weakness in chemicals and food. Full-year guidance is reaffirmed, with ongoing share buybacks and a stable dividend policy.
-
Q1 FY2025 saw higher sales and profits year-over-year, led by strong Life Science segment growth and resilient pricing, despite challenges in chemicals and food products. Full-year guidance remains unchanged, with a share buyback announced.
Fiscal Year 2025
-
FY2024 delivered record sales and profit, with growth across the chemical businesses. FY2025 guidance anticipates further consolidated growth, while tariffs, input costs, and higher R&D and depreciation costs weigh on select segments.
-
Q3 sales and operating profit increased YoY, with profit growth across core businesses despite declines in Food Products and Life Science sales. FY2024 guidance was maintained, while semiconductor materials investment and organizational focus continue.
-
H1 sales and profit increased, led by polymer additives and environmental materials. FY2024 profit guidance and dividends were raised, with semiconductor demand and new product launches supporting growth plans.
-
Q1 saw YoY growth in sales and profit, with strong performance in Polymer Additives, Functional Chemicals, and Food Products, but a loss in Life Science. Full-year guidance was raised for the first half, with continued focus on semiconductors and environmental materials.
Fiscal Year 2024
-
FY2023 operating and current profit reached records despite slightly lower sales. FY2024 guidance anticipates growth, while ADX 2026 targets JPY 500 billion in sales and JPY 53 billion in operating profit, backed by substantial investment.
-
Q3 sales declined, but pricing and FX helped profits grow amid volume and cost pressures. FY2023 guidance was unchanged, with food products recovery and advanced semiconductor investment supporting the outlook.
-
Q1 sales and profit declined as lower volumes and weak chemicals demand outweighed pricing and FX benefits. FY2023 sales and operating profit forecasts stayed unchanged, with lower H1 expectations offset by stronger H2 forecasts.document-source0178